Gregory Rockson: Celebrating Black Excellence In Entrepreneurship

Gregory Rockson is a Ghanaian entrepreneur exploring the world of medicine through pharmaceutical provision of e-prescription network in emerging markets with Pfizer and Africa. Novartis as his major pharmaceutical clientele. He is the co-founder and CEO of mPharma, a company on the mission of giving a replica of Silicon Valley in the area of healthcare delivery in Africa.

mPharma doesn’t just provide analytical data to drug companies and health ministries; the company is building an infrastructure and a drug monitoring system that connects patients, hospitals and pharmacies to a cloud-based software. Doctors know in real-time the exact location and availability of any medication of interest, and patients have a more reliable access to medicines.

With about eight (8) years of operation, mPharma has its presence in three African countries (Nigeria, Ghana and Zambia), serving close to 45,000 patients each month across a network of over 80 hospitals and clinics in Lagos, Warri, Port Harcourt, Benin, Aba, Accra, Kumasi, Cape Coast, Lusaka and Ndola. mPharma aims to build the data intelligence and retail layer to support the future of African healthcare.

He formerly founded Big Brother Big Sister in Denmark, a mentorship program for refugee kids, and the Six Days of Peace Project in the Middle East, culminating in a meeting between Israeli and Palestinian diplomats. A World Economic Forum Global Shaper, he was a PPIA Fellow in Princeton University’s Woodrow Wilson School and a Rotary Scholar at University of Copenhagen. He holds a degree in political science and philosophy.

In 2020, Rockson was listed among the 100 most influential young Africans by Avance Media.

Share on facebook
Share on twitter
Share on pinterest
Share on linkedin
Share on whatsapp
Share on email

Leave a Comment

WeCreativez WhatsApp Support
Our support team is here to answer your questions. Ask us anything!
👋 Hi, how can I help?

SUBSCRIBE TO OUR NEWSLETTER

Register today and be among the first to get exclusive news and reports